Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
155 hedge funds and large institutions have $1.21B invested in Momenta Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 59 increasing their positions, 38 reducing their positions, and 15 closing their positions.
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
55% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 38
5% more funds holding
Funds holding: 147 → 155 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less call options, than puts
Call options by funds: $984K | Put options by funds: $1.01M
15% less capital invested
Capital invested by funds: $1.42B → $1.21B (-$218M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$10.7M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.02M |
| 3 |
BlackRock
New York
|
+$5.82M |
| 4 |
Morgan Stanley
New York
|
+$5.36M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$37.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$10.6M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$6.64M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.11M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.84M |
MNTA Hedge Fund Activity: Q2 2019 in Review
155 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q2 2019, worth a combined $1.21B — down 15% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new MNTA positions and 15 closed out — a net gain of 10 holders — while 59 added to existing stakes and 38 trimmed.
The largest buyer was Peregrine Capital Management, opening a new position worth an estimated $10.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $37.3M sold.
- 155 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q2 2019, up from 147 in Q1 2019.
- Funds reported $1.21B of Momenta Pharmaceuticals, Inc. stock for Q2 2019, down 15% quarter-over-quarter.
- 25 funds opened new Momenta Pharmaceuticals, Inc. positions in Q2 2019 and 15 closed out, a net change of +10 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q2 2019 was Peregrine Capital Management, an estimated $10.7M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q2 2019 was RA Capital Management, an estimated $37.3M sold.
Based on aggregated 13F filings for Q2 2019.